BRPI0414043A - tratamento de cáncer com epotilonas - Google Patents

tratamento de cáncer com epotilonas

Info

Publication number
BRPI0414043A
BRPI0414043A BRPI0414043-5A BRPI0414043A BRPI0414043A BR PI0414043 A BRPI0414043 A BR PI0414043A BR PI0414043 A BRPI0414043 A BR PI0414043A BR PI0414043 A BRPI0414043 A BR PI0414043A
Authority
BR
Brazil
Prior art keywords
epothilone
cancer treatment
treatment
dose
epotilones
Prior art date
Application number
BRPI0414043-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Clifford Dilea
Paul M J Mcsheehy
Sauveur-Michel Maira
Chiaki Tanaka
Markus Wartmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0414043A publication Critical patent/BRPI0414043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0414043-5A 2003-09-02 2004-09-01 tratamento de cáncer com epotilonas BRPI0414043A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49954803P 2003-09-02 2003-09-02
PCT/EP2004/009737 WO2005020989A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Publications (1)

Publication Number Publication Date
BRPI0414043A true BRPI0414043A (pt) 2006-10-24

Family

ID=34272839

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414043-5A BRPI0414043A (pt) 2003-09-02 2004-09-01 tratamento de cáncer com epotilonas

Country Status (9)

Country Link
US (2) US20060235059A1 (https=)
EP (1) EP1663214A1 (https=)
JP (1) JP2007504259A (https=)
CN (1) CN1870995A (https=)
AU (1) AU2004268377B2 (https=)
BR (1) BRPI0414043A (https=)
CA (1) CA2537057A1 (https=)
MX (1) MXPA06002393A (https=)
WO (1) WO2005020989A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011084521A2 (en) * 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
ES2304240T3 (es) * 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
MXPA04006822A (es) * 2002-01-14 2004-12-08 Novartis Ag Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1503756B1 (en) * 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN101389334A (zh) * 2002-05-20 2009-03-18 高山生物科学股份有限公司 埃坡霉素d的给药方法
BR0313198A (pt) * 2002-08-02 2005-07-12 Novartis Ag Derivados de epotilona
BR0317150A (pt) * 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas

Also Published As

Publication number Publication date
US20060235059A1 (en) 2006-10-19
MXPA06002393A (es) 2006-06-20
EP1663214A1 (en) 2006-06-07
JP2007504259A (ja) 2007-03-01
AU2004268377B2 (en) 2008-06-26
CA2537057A1 (en) 2005-03-10
US20090069394A1 (en) 2009-03-12
CN1870995A (zh) 2006-11-29
WO2005020989A1 (en) 2005-03-10
AU2004268377A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
BRPI0414043A (pt) tratamento de cáncer com epotilonas
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
BR112015022820A8 (pt) ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0513551A (pt) uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral
BR0215168A (pt) Métodos para retardar a senescência e tratamento e prevenção de doenças associadas com senescência
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
MX2010002971A (es) Metodo para inhibir la reabsorcion del hueso.
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
NZ588913A (en) Liver cancer drug
CO6361917A2 (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
NZ598489A (en) Combination therapy for treating proliferative diseases
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
BR112022015151A2 (pt) Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
BR112012008325A2 (pt) N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
BR0308154A (pt) Emprego de epotilonas no tratamento de doenças cerebrais associadas com processos proliferativos
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
BRPI0607043A2 (pt) lacosamida para terapia de adição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.